Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
11.15
+0.97 (9.53%)
At close: Jun 27, 2025, 4:00 PM
11.20
+0.05 (0.45%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Capricor Therapeutics Employees
Capricor Therapeutics had 160 employees as of December 31, 2024. The number of employees increased by 58 or 56.86% compared to the previous year.
Employees
160
Change (1Y)
58
Growth (1Y)
56.86%
Revenue / Employee
$108,522
Profits / Employee
-$344,154
Market Cap
509.64M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CAPR News
- 4 days ago - FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy - Benzinga
- 4 days ago - US FDA will not convene expert panel for Capricor Therapeutics' DMD cell therapy - Reuters
- 5 days ago - Why Is Capricor Therapeutics Stock Trading Lower On Monday? - Benzinga
- 8 days ago - Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients - Benzinga
- 8 days ago - Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy - GlobeNewsWire
- 11 days ago - Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program - GlobeNewsWire
- 16 days ago - Capricor: A Hold Rating With Regulatory FDA Form Given For Deramiocel Advancement - Seeking Alpha
- 17 days ago - Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program - GlobeNewsWire